A newly developed method to accurately quantify how much radiation is absorbed by the blood during cancer treatment could lead to more personalised, preventive, and safer radiotherapy.
Some medications can only be taken as an injection, which is often painful, unpleasant and inconvenient for patients. A new transport system could make it possible to swap these injections for pills.
Defining four different immunologic subtypes of recurrent ovarian cancers, researchers pave the way for more personalized treatment.
Common respiratory infections such as influenza and Covid-19 can awaken dormant breast cancer cells that have spread to the lungs, setting the stage for new metastatic tumors, new research finds.
Molecular profiling of over 1,000 nasopharyngeal cancer (NPC) tumours reveals distinct differences in tumour microenvironment of locoregionally advanced NPC, supporting personalised treatment.
Tongue squamous cell carcinoma, the most common type of oral cancer, is a challenging target for immunotherapies. Researchers now identified five immunotypes to better predict treatment response.
From organ-preserving treatments to chemo-immunotherapy combinations: five studies presented at ESTRO 2025 showcase how radiotherapy is reshaping the treatment landscape for anal and rectal cancer.
Bringing diagnostics and therapy closer together - that is the basic concept behind theranostics. Through further development of its PET/MR scanners, Siemens Healthineers aims to advance this approach. Andreas Schneck, Head of the MRI Division at Siemens Healthineers, talks about the new system, which was also presented at the European Congress of Radiology (ECR) in Vienna, and its advantages in…
Unprecedented insights into the inner workings of an early-stage lung tumor: An international research team describes a new method for 3D mapping cellular interactions in the tumor microenvironment.
Pancreatic cancer is one of the most aggressive cancers, partly due to its tumor microenvironment, known as the stroma. Now, a study has identified a new key factor contributing to this feature.
Researchers developed biomimetic materials inspired by lymph nodes, which could improve cancer immunotherapy. The study highlights the potential of bioengineered scaffolds for cell-based therapies.
Researchers discovered a key mechanism by which melanomas and other aggressive tumours prevent the immune system from detecting and attacking them – one of the greatest challenges in oncology today.
Molecular changes associated with brain inflammation and dementia can be detected in the blood. Researchers want to use this to establish blood tests as an alternative to more costly brain scans.
The gastrointestinal microbiome holds valuable information that can help predict whether immunotherapy will be successful against melanoma. A new “gut-on-a-chip” is designed to do exactly that.
Researchers have developed a new kind of tumour-on-a-chip, which gives insight into the tumour environment and immunotherapy response. The device has been successfully tested on breast cancer samples.
“What is a tumour?” Researchers explore tumour architecture as a valuable source of information to understand tumour dynamics and predict its sensitivity to anticancer drugs.
The immune system of children reacts differently to cancer than that of adults. New insights into these differences have the potential to lead to new tailored treatments for children with cancer.
A new personalised oncology platform has been tested to detect circulating tumour DNA (ctDNA) in patients with lung adenocarcinoma before surgery, to predict their risk of cancer relapse.
Why does radiation therapy kill cancer cells from the same tumour in different ways? This has long remained poorly understood. Now, new findings open up opportunities to improve treatment.
Researchers have developed an AI-based model to better predict whether cancer patients will benefit from immunotherapy — using only routine blood tests and clinical data.
A molecule called MR1 (MHC Class I-related Molecule 1) enables a newly-discovered type of T-cells to sense differences in the metabolism that occur when cells become cancerous.
Researchers now succeeded in making leukemia-specific immune cells less sensitive to the influence of tumor cells, thereby significantly increasing their effectiveness.
A new radiotracer – an injected compound used in PET scans – could help inform doctors that a patients aggressive cancer will not respond to chemotherapy before treatment is given.
Research offers new insights into harnessing the immune system to combat ovarian cancer. The findings could lead to personalized therapies that target the right patients at the right time.
When women are pregnant and nurse their babies, their bodies change to ensure the health of both mother and child. Researchers now surprisingly find that the intestine also changes completely.
New insights into the previously unknown diversity of cancer-associated fibroblasts in basal cell carcinoma, squamous cell carcinoma and melanoma could pave the way for new therapies.
A new approach to fight glioblastoma: Swiss researchers have now developed an immunotherapy that not only attacks the brain tumor—it also turns its microenvironment against it.
PET/CT image analysis using artificial intelligence (AI) can predict the occurrence of interstitial lung disease, a serious side effect of immunotherapy in lung cancer, a new study shows.
Protection against blood clots: A new material, designed to mimic blood vessels, could allow for safer use of devices like catheters, stents, blood-oxygenation machines and dialysis machines.
A new method could open new avenues to quick, affordable cancer diagnosis, US researchers report. The method uses ultrathin membranes to capture extracellular vesicles.
Immunotherapy has become the most promising strategy for treating several cancers, but its effectiveness is still very uneven. Three researchers explain how research is being done to change this.
Scientists at the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG) have developed CAR-T cells capable of targeting malignant gliomas while preserving healthy tissue.
STAb-T, a new form of immunotherapy to treat solid tumours shows therapeutic potential in animal models with non-small cell lung cancer. The new strategy is designed to strengthen the defensive cells.
Only 20-40% of patients respond positively to immunotherapy, and these rates vary across different types of cancer. Researchers now identified five key factors that determine response and survival.
Currently, it is difficult to predict whether a cancer patient will respond to immunotherapy or not. A new method to quantify the heterogeneity of the tumour microenvironment aims to improve this.
Researchers have identified fibrotic scarring as a key source of resurgence of glioblastoma multiforme (GBM). The new insights could lead to better prevention of this type of brain cancer.
A US-Swiss team leverages AI and molecular simulations to uncover new pathways for precision cancer treatments, paving the way for more effective, personalized therapies.
In rhesus pregnancy, antibodies from the pregnant mother can lead to anaemia for the foetus in the uterus. A new study suggests that a drug could serve as a non-surgical alternative.
Researchers have discovered an Achilles heel of migratory metastatic cells: They now investigate how the cell death mechanism ferroptosis can be utilized for future cancer treatments.
Why does the immune system sometimes fail to control the development of bowel cancer? UK and Dutch researchers discovered how cancer cells use a genetic "switch" to evade detection.
The IRCCS in Bologna has inaugurated a state-of-the-art integrated PET/CT system. This cutting-edge technology allows for the entire human body to be studied in a single scan, even detecting the smallest tumour cells.
Pancreatic cancer stem cells exploit an antibacterial protein to evade the immune system. Removing this protein could pave the way to more effective immunotherapy, new research suggests.
Immunotherapy increases survival rates in kidney cancer, but does not work for everyone. A research team developed a new method to predict which patients will benefit from it.
Chemotherapy kills cancer cells – but how? New research suggests that the mechanisms are different than previously understood. The finding will have implications for future cancer treatments.
Researchers developed a new type of anticoagulant whose action can be rapidly stopped. This reversible activity could revolutionise the use of anticoagulants in surgery or other applications.
Digital pathology can be used to great effect in pharmaceutical research: it can accelerate analyses, give deeper insights into cellular mechanisms, and enable better understanding of their role into clinical development. This potentially offers clearer predictions on how patients may respond to treatment and lead to personalized therapies.
Bacteria can help – or hinder – the treatment of cancer. How this happens, however, is largely unknown. Now, researchers have mapped bacteria in cancer metastases to shed more light on their role.
In diagnostics, there used to be a hard divide between radiology and pathology, where methods were largely considered incompatible with one another. However, to pave the way for next-generation diagnosis, Professor Regina Beets-Tan urged both sides to come out from their trenches and appreciate the synergies the fields have to offer. In her presentation at the European Congress of Radiology (ECR)…
When it comes to lung cancer care, patients in Europe face significant differences depending on the country they are in. Researchers from Amsterdam analysed the landscape.
In a breakthrough for personalised oncology, scientists have developed and demonstrated a novel platform that can significantly reduce the time needed to determine the efficacy of anti-cancer drugs.
Researchers have unveiled a detailed understanding of immune responses in cancer, potentially paving the way for the development of new therapeutic strategies, the team hopes.
Researchers in Japan and the US have developed technology to robustly augment the amount of MHC class I molecules in cancer cells. This makes them easier to find and destroy for the immune system.
Chemotherapy against cancer can lead to the generation of senescent tumour cells, which can help the tumour survive. A new immunotherapy approach to eliminate these cells shows promise in animal models.
Contraception, wound healing, arthritis treatment: Here are three recent papers published in ACS journals that could expand the beneficial uses for nanoparticles, based on results in rats.
Scientists map the effects of 86 immune-signaling molecules called cytokines on every major immune cell type, creating a reference for studying the inner workings of the immune system.
In a new study, UCLA researchers demonstrated how small cell neuroendocrine prostate cancer tumor cells can arise from less aggressive prostate tumors.
Diagnosing early-stage lung cancer with low-dose CT screening dramatically improves the long-term survival rate of cancer patients, a large-scale, 20-year international study shows.
Chemotherapy, radiotherapy or surgery – these are the three common forms of cancer therapy. Now, lymphoma specialists in Essen are investigating the possibility of a different approach.
US researchers have discovered that radiation therapy combined with two types of immunotherapy can control tumors in preclinical models of triple negative breast cancer.
A new onco-therapeutic vaccine candidate against human papillomavirus (HPV)-induced cancers, such as cervical and oropharyngeal cancers, has shown promising results in the preclinical phase.
For the first time, researchers show that AI-based predictions can deliver comparable results to clinical tests on biopsies of patients with colorectal cancer (CRC).
Patients with immunodeficiency cannot benefit from conventional Covid-19 vaccines and still at risk from infection. A promising new approach now brings hope for this patient group.
A family physician at Tufts University School of Medicine offers advice for how to treat allergies and how to tell if symptoms are due to allergies, the common cold, the flu, or Covid-19.
While screening programs for several of the commonest cancers are now well established, lung cancer screening has yet to reach anywhere near the same proportion of at-risk patients.
An 'encyclopaedia' of protein alterations in soft tissue sarcomas could open the door to a new era of understanding and treatment for this group of rare cancers.
Chimeric antigen receptor (CAR) T-cell therapy is an immunotherapy treatment that re-engineers a patient’s own T-cells to help them attack malignant tumour cells. It has been very effective in the treatment of blood cancers, including certain types of leukaemia and lymphoma. However, two serious side effects are common as a result of the treatment: cytokine release syndrome (CRS) and immune…
US researchers identified a potential breakthrough in glioblastoma treatment. Using a modified virus, they created a treatment that specifically attacks tumor cells, while leaving normal cells intact.
French scientists discovered that CD4 T cells generated during immunotherapy are capable of remotely neutralizing tumor cells by producing interferon gamma (IFN-γ).
Unanswered questions are hampering clinicians in their efforts to get the best out of a precision medicine approach for their patients. Speaking at the Genomics and Precision Medicine Expo in London at the end of May, cancer educator Dr Elaine Vickers said the benefits of being matched to an investigational drug remain questionable for most people with advanced cancer.
A group of researchers has illustrated the mechanistic pathway for PTEN-deficient breast cancer and successfully tested a method of countering the downstream effects of immune system evasion by tumors.
A new class of immunotherapy shows promising results for fighting the most aggressive form of skin cancer.
For decades, researchers have marveled at the ability of glioblastoma, a particularly aggressive brain cancer, to turn off a patient's cancer-fighting immune cells, thereby allowing tumors to grow freely.
For pancreatic cancer, the effect of immunotherapy is limited and differs between men and women. Researchers at Karolinska Institutet have now found a possible explanation for this sex difference.
Researchers in Frankfurt have now been able to show how ferroptosis can be used to make immunotherapies against liver cancer more effective in mice.
Scientists are developing a new kind of light-activated cancer treatments. This would work by switching on LED lights embedded close to a tumour, which would then activate biotherapeutic drugs.
The newly founded UK Focused Ultrasound Foundation is dedicated to advancing the development and adoption of the technology, which can be used to non-invasively treat tissue deep in the body.
Evidence that radioembolization, a trans-arterial therapy, is safe and stops disease progression in metastatic breast cancer is increasing, a prominent American interventional radiologist showed at the Spectrum conference in Miami.
Focused ultrasound (FUS) ablation is an emerging treatment for breast tumours. Its use was highlighted in an October webinar focused on emerging immunotherapy research and breast cancer.
Dutch scientists have discovered how specialized immune cells can detect and remove cancers that are ‘invisible’ to the conventional defense mechanisms of the immune system.
Immunotherapy prior to surgery is surprisingly effective for patients with a certain type of colorectal cancer (dMMR/MSI-H CRC). These new study results contrast current treatment regimens.
Dutch scientists have performed whole-body PET scans using a radioactively labeled antibody tracer against immune cells, to predict the effect of treatment with immune checkpoint inhibitors.
Canadian researchers have developed a new method of killing brain cancer cells while preserving the tissue around it. A remarkable side-benefit: chemotherapy of the cancer suddenly becomes possible.
This summer, The European Commission launched I3lung, a new research initiative as a part of Horizon Europe, the EU’s research and innovation program. This research initiative aims to create a cutting-edge, decision-making tool to help clinicians and patients select the best lung cancer treatment based on each patient’s specific needs and circumstances.
Researchers in Barcelona discovered the population of residual tumour cells responsible for the recurrence of colorectal cancer in other organs after removal of the primary tumour.
Researchers from Barcelona report that vaccination with senescent cells shows promise in experimental models of melanoma and pancreatic cancer.
99mTc-Sestamibi SPECT/CT can aid in the diagnosis of solid renal lesions, especially in cases where contrast enhanced CT findings are inconclusive, according to researchers from the Mallinckrodt Institute of Radiology at Washington University School of Medicine in St. Louis, Missouri.
Some leukemias evade treatment by changing their appearance and identity through changing the read-out of their DNA, a new study has found.
Scientists have discovered that cervical cancer can be divided into 2 distinct molecular subgroups – one far more aggressive than the other – as part of the largest ‘omics’ study of its kind.
UC San Francisco researchers have developed a drug marking cancer cells for destruction by the immune system.
A new study led by researchers in Barcelona has determined the protein TIMP-1 as a valuable biomarker for the progression of lung adenocarcinoma. The results open the door to new treatments.
A new device, which doesn’t rely on immunosuppressing drugs, may assist efforts to develop an artificial pancreas to treat diabetes.
As knowledge about Covid-19 advances, so does the arsenal of techniques to predict, diagnose and follow up on the disease. At ECR, researchers presented a range of promising imaging modalities to keep track of Covid-19 symptoms, severity, and mortality, often including AI support to enhance or accelerate diagnostics.
Cancer immunotherapy is a successful treatment form in oncology, but it doesn't work for every patient. One problem may be the lack of a specific type of immune cell in the tumor, researchers found.
A simple blood test could be a better predictor of whether cancer immunotherapy will be successful for a patient with lung cancer than an invasive tumor biopsy procedure.
Researchers have developed an ultrasound-guided cancer immunotherapy platform that generates systemic antitumor immunity and improves the therapeutic efficacy of immune checkpoint blockade.
"Crown-like structures" surrounding breast tumors in overweight and obese patients could hinder their response to therapy. The findings of this study could potentially be used to improve personalized treatment for patients.
Computational approaches are being applied on enormous amounts of data from sequencing technologies to develop tools to help clinicians manage cancer more effectively.
During a webinar, health experts and clinicians highlighted the need for urgent changes to lung cancer services across Europe to create a more cohesive and equal approach to care.
Delivering a drug directly inside a lesion using minimally invasive procedures opens up new perspectives for patients and medical teams. At ECR Overture, experts looked at how to best join forces to advance the field of interventional oncology.
Bioengineers have shown they can eradicate advanced-stage ovarian and colorectal cancer in mice in as little as six days with a treatment that could be ready for human clinical trials later this year.
A biocompatible ultrasound transducer chip could be a more effective way to harness the technology for biomedical applications.
Children's National Hospital successfully performed the first-ever high-intensity focused ultrasound surgery on a pediatric patient with neurofibromatosis. This is the youngest patient to undergo HIFU treatment in the world.
French researchers have found a way to facilitate access to tumours for killer lymphocytes, paving the way for more efficient immunotherapies against cancer.
In multiple myeloma, a cancer of the bone marrow, relapse almost always occurs after treatment. Initially, most patients respond well to therapy. However, as the disease progresses, resistant cancer cells spread in the bone marrow, with fatal consequences for the patients. Scientists at the German Cancer Research Center (DKFZ), Heidelberg University Hospital (UKHD) and the National Center for…
Professor Regina Beets-Tan, President of the European Society of Radiology (ESR), looks on possible future developments in cancer imaging. AI is very promising in this regard, 'However, it has proven to be a problem that the data with which the artificial intelligence is fed must be very homogeneous,' the expert observes.
For nuclear medicine specialists, 2021 may be heralded as a banner year validating the use of theranostic technology to treat cancer. Long-awaited results from the international phase 3 clinical VISION trial spark confidence in many experts.
Classic antidepressants could help improve modern cancer treatments. They slowed the growth of pancreatic and colon cancers in mice, and when combined with immunotherapy, they even stopped the cancer growth long-term. In some cases the tumors disappeared completely, researchers at the University of Zurich (UZH) and University Hospital Zurich (USZ) have found. Their findings will now be tested in…
Hokkaido University scientists and colleagues in Japan have found a way that could help some patients overcome resistance to an immunotherapy treatment for cancer. The approach, proven in mice experiments, was reported in the Journal for Immunotherapy of Cancer.
A team led by the Garvan Institute of Medical Research has revealed a new approach for classifying breast cancer subtypes based on their cell profile, which could help personalise treatments for patients. By analysing breast cancer biopsies from patients at Sydney hospitals, the researchers revealed more than 50 distinct cancer, immune and connective cell types and states, which could assign…
A new technology that can study which therapies will work on patients with solid cancerous tumours has been developed by scientists at University College London (UCL). Researchers say the tool, which can rapidly test tumorous tissue against different treatments, such as chemotherapy, immunotherapy or radiotherapy, could be used by clinicians to pinpoint the best therapy for a particular patient.
Cancer patients’ medical records can often comprise up to 100 terabytes of individual — and usually very heterogeneous — data, including blood and tumor values, personal indicators, sequencing and treatment data, and much more besides. Up to now, it has been virtually impossible to use this wealth of information efficiently due to a lack of appropriate processing mechanisms. As a result,…
Pancreatic cancer is one of the deadliest cancers in the world, and one of the most difficult to treat. In 2020, an estimated 495,000 individuals worldwide were diagnosed with pancreatic cancer and an estimated 466,000 died, according to statistics from the World Health Organization’s International Agency for Research on Cancer. Most patients with advanced disease die within a year of…
Miniature tumours in the lab are able to predict whether the corresponding real-life patients will benefit from immunotherapy. “We’ve solved a major problem many scientists had been facing: preserving a tumours original composition and structure outside of the patient in the lab”, says cancer researcher Daniela Thommen.
Uppsala University scientists have designed a new mouse model that facilitates study of factors contributing to the progression of human bladder cancer and of immune-system activation when the tumour is growing. Using this model, they have been able to study how proteins change before, while and after a tumour develops in the bladder wall. The study has now been published in the scientific…
Researchers have identified a way to improve the immune response in the face of severe viral infections. It is widely known that severe viral infections and cancer cause impairments to the immune system, including to T cells, a process called immune ‘exhaustion’. Overcoming immune exhaustion is a major goal for the development of new therapies for cancer or severe viral infections.
Queen Máxima of the Netherlands, after whom the Princess Máxima Center for Pediatric Oncology in Utrecht is named, along with several representatives of the center, the Hopp Children’s Cancer Center Heidelberg (KiTZ), University Hospital Heidelberg (UKHD) and the German Cancer Research Center (DKFZ), signed a memorandum on strategic cooperation in the field of pediatric oncology in Europe at…
Monash University researchers have provided a fundamental advance regarding how T cells become activated when encountering pathogens such as viruses.
Genetically enhancing a patient's immune cells by adding therapeutic genes to them outside the body is regarded as a promising new treatment approach in oncology. However, the production of these therapeutic cells using viruses is not only expensive but time-consuming. Researchers at the German Cancer Research Center (DKFZ) have developed an innovative non-viral vector that can efficiently…
Tumor vaccines can help the body fight cancer. Mutations in the tumor genome often lead to protein changes that are typical of cancer. A vaccine can alert the patients' immune system to these mutated proteins. For the first time, physicians and cancer researchers from Heidelberg and Mannheim have now carried out a clinical trial to test a mutation-specific vaccine against malignant brain tumors.…
The Institute for Research in Biomedicine (IRB) in Switzerland developed a second-generation ‘double antibody’ that protects from SARS-CoV-2, the virus causing Covid-19, and all its tested variants. It also prevents the virus from mutating to resist the therapy. Antibody-based immunotherapy was already shown to be effective against Covid-19 but faces two main obstacles: it needs to work…
Lung tumors are home to immune cells that affect their growth and resistance to treatment. Looking at neutrophils, scientists led by EPFL have discovered that the key might lie in the cells’ ability to metabolize glucose, opening an entirely new target for improving radiotherapy.
Rapid tests, PCR tests, self-tests… there are many test options to determine contamination with Covid-19. In most this is done by inserting a cotton swab deep into the nose and/or throat to extract some mucus – unpleasant for adults and often a drama for children. Towards the end of 2020, a new system emerged to rule out a Covid-19 contamination. The electronic SpiroNose performs a…
Researchers at the Universitat Autònoma de Barcelona obtained a highly accurate recreation of human glioblastoma’s features using a novel 3D microscopy analysis. The study, published in the journal Acta Neuropathologica Communications, provides new information to help with the diagnose, by finding therapeutical targets and designing immunotherapeutical strategies.
A new EU-wide repository for health-related imaging data could boost development and marketing of AI tools for better cancer management. The open-source database will collect and harmonise images acquired from 40,000 patients, spanning different countries, modalities and equipment. This approach could eliminate one of the major bottlenecks in the clinical adoption of AI today: Data bias.
A new generation of tissue microarrays are delivering more efficient and time-effective solutions to answering complex clinical and scientific questions. Sitting at the core of this new approach is digital pathology, allowing specific and targeted analysis of small areas of tissue.
The advent of digital pathology is offering a unique opportunity to develop computerized image analysis methods to diagnose disease and predict outcomes for cancer patients from histopathology tissue sections. Such advances can help predict risk of recurrence, disease aggressiveness and long-term survival, according to a leading expert in the field, Professor Anant Madabhushi from Case Western…
A microbe found in the colon and commonly associated with the development of colitis and colon cancer also may play a role in the development of some breast cancers, according to new research from investigators with the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy. Breast tissue cells exposed to this toxin retain a long-term memory, increasing the…
Doctors at Addenbrooke’s Hospital in Cambridge aim to drastically cut cancer waiting times by using artificial intelligence (AI) to automate lengthy radiotherapy preparations. The AI technology, known as InnerEye, is the result of an eight-year collaboration between researchers at Cambridge-based Microsoft Research, Addenbrooke’s Hospital and the University of Cambridge.
A study of over a thousand cancer patients treated with immunotherapy drugs has found these patients are at greater risk of heart problems, including death from heart attack or stroke. The patients had either lung cancer or malignant melanoma (a type of skin cancer), for which immune checkpoint inhibitors such as a programmed cell death-1 (PD1) inhibitors or cytotoxic T-lymphocyte-associated…
Scientists report on their detailed look at B cells' presence inside tumors. B cells represent the other major arm of the adaptive immune system, besides T cells, and could offer opportunities for new treatments against some kinds of cancers.
The evolving area of immunotherapies in lung cancer and the role of iRecist treatment assessment protocols were investigated during a virtual session organised by the British Institute of Radiology (BIR). Consultant radiologist Dr Charlie Sayer, specialist in lung cancer imaging at the Brighton and Sussex University Hospitals Trust, South of England, focused on immunotherapies, the limitations of…
Pancreatic cancer has the worst survival rate of any cancers, with immunotherapies currently offering negligible treatment benefits for patients. To help identify new therapeutic approaches, researchers from the University of Oxford have been focusing on leukocyte infiltration as a prognostic marker of the disease. Their study and findings were outlined by Dr Shivan Sivakumar during a session…
Experts have identified two distinct immunological and cellular profiles in the lungs of Covid-19 patients which they believe could help define treatment pathways. From some of the earliest Covid-19 autopsies conducted in Europe, Swiss-based researchers have performed integrative digital pathology and transcriptomic analyses of lung tissues of 16 coronavirus patients who died from respiratory…
An autoimmune side effect of immune checkpoint inhibitor (ICI) drugs could signal improved control of kidney cancer, according to a new study by researchers in UT Southwestern's Kidney Cancer Program (KCP).
Launched in 2011, the Pan-Cancer Project, involved more than 1,300 scientists and clinicians in 37 countries, and analysed more than 2,600 genomes of 38 tumour types. Discovery: The first indications of cancer development can be found in genes at a very early stage, which triggers new opportunities for treatment.
Researchers have found that a class of commonly-used heart drugs may also improve patients’ responses to anti-cancer immunotherapies called PD(L)1 inhibitors, according to preliminary findings to be presented at the 32th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
The COVID-19 pandemic has impacted virtually every aspect of cancer care and research– from introducing new risks for cancer patients to disrupting the delivery of cancer treatment and the continuity of cancer research.
Spatial analytics offers greater clarity in the assessment of tumours beyond routine microscopic analysis. High-capacity digital image analysis enables new methods of spatial statistics to extract features not immediately distinguishable by visual inspection. These subvisual features reflect complex properties, such as intratumour heterogeneity and have the additional benefit that they can target…
Better outcomes, more favourable prognoses – oncologists and their lung cancer patients didn’t dare to dream about it. Finally, there might be hope. The so-called checkpoint inhibitors (immunotherapy drug) have been used successfully, albeit not for every patient. They are a double-edged sword, with risks as well as opportunities, as explained by Professor Cornelia Schäfer-Prokop.
It remains one of the key questions of the current corona pandemic: Why do people infected with SARS-CoV-2 experience varying degrees of COVID-19, the disease which it triggers? Researchers, led by Professor Mascha Binder from University Hospital Halle (Saale), have investigated more than 14 million receptor sequences of B and T cells, i.e. immune cells, obtained from blood samples of COVID-19…
The COVID-19 pandemic has affected virtually every aspect of healthcare provision - cancer care is no exception. In fact, during the pandemic, patients with cancer represent a high-risk group. Recent studies estimate that delays in cancer diagnosis and treatment will increase the indirect death toll of COVID-19 by several thousands in the coming years.
A recent study conducted by the Faculty of Medicine at The Chinese University of Hong Kong (CU Medicine) discovered a novel genetic biomarker which can predict the survival of head and neck cancer patients. There are over 0.7 million new head and neck squamous cell carcinoma (HNSCC) cases globally each year. However, currently there is no clinical implementation of any genetic biomarker to…
Why does every person react differently to an infection with the coronavirus SARS-CoV-2? Why do some people have no symptoms or only mild symptoms of COVID-19, the disease which it causes? And why do some people become so severely ill that they require ventilators or even die? These questions are being investigated by Professor Mascha Binder, director of the Department of Internal Medicine IV at…
Our immune system not only protects us against infection, but also against cancer. This powerful protection is based in particular on the activation of special cells of the immune system, CD8+ T cells. These cells recognize infected or cancer cells and kill them specifically. “The ability of the immune system and especially CD8+ T cells to eliminate cancer cells in tissues such as the lung, gut…
People who are at high risk of developing lung cancer, such as heavy smokers, are routinely screened with computed tomography (CT), which can detect tumors in the lungs. However, this test has an extremely high rate of false positives, as it also picks up benign nodules in the lungs. Researchers at the Massachussetts Institute of Technology (MIT) have now developed a new approach to early…
The human immune system can recognize and eliminate not only germs but also cancer cells. This is why treatments with weakened germs can help the immune system in its fight against cancer. Researchers at the Max Planck Institute for Infection Biology in Berlin have genetically modified the tuberculosis vaccine BCG in a way that it stimulates the immune system more specifically. Consequently, the…
The British Heart Foundation (BHF) announced its shortlist of four research projects competing for a single £30 million award. The charity says it is one of many radical new approaches needed to address a frightening mismatch in research funding compared with the burden of heart and circulatory diseases. With the World Health Organization forecasting an increase in cardiovascular deaths…
Researchers at Cardiff University have discovered a new type of killer T-cell that offers hope of a “one-size-fits-all” cancer therapy. T-cell therapies for cancer - where immune cells are removed, modified and returned to the patient’s blood to seek and destroy cancer cells - are the latest paradigm in cancer treatments. The most widely-used therapy, known as CAR-T, is personalised to each…
How can the treatment of soft tissue sarcomas, these particularly resistant and aggressive forms of cancer, be improved and better personalized? An international team led by Wolf Hervé Fridman with researchers from Inserm, Sorbonne Université and Université de Paris at the Cordeliers Research Center, in collaboration with the French League against cancer and Institut Bergonié, has shown that…
A team of researchers from the National University of Singapore (NUS) has discovered a new personalised tool to detect cancer, predict patient survivability and how well a cancer patient would respond to immunotherapy. This tool is a specially-designed cancer 'scorecard' to be used with the standard blood test for cancer (also known as liquid biopsy). This 'scorecard', which the team termed as…
Doctors have used focused ultrasound to destroy tumors in the body without invasive surgery for some time. However, the therapeutic ultrasound used in clinics today indiscriminately damages cancer and healthy cells alike. Most forms of ultrasound-based therapies either use high-intensity beams to heat and destroy cells or special contrast agents that are injected prior to ultrasound, which can…
Researchers at the Icahn School of Medicine at Mount Sinai have discovered a way to move precision immunotherapy forward by using genomics to inform immunotherapy for multiple myeloma, a blood cancer, according to a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research, in December. This is the first study to experimentally determine which…
An enthralling insight into the care that could be offered to cancer patients of the future was presented by cancer imaging expert Professor Regina Beets-Tan during her a keynote presentation at the recent British Institute of Radiology congress. In the session ‘Oncologic imaging: Future perspectives’, the professor outlined what a Multi-Disciplinary Team (MDT) of the future – a team in…
Scientists from the Case Western Reserve University digital imaging lab use Artificial Intelligence (AI) to predict which lung-cancer patients will benefit from expensive immunotherapy. This is done by teaching a computer to find previously unseen changes in patterns in CT scans taken when the lung cancer is first diagnosed compared to scans taken after the first 2-3 cycles of immunotherapy…
Advances in antiretroviral therapy mean that today, people infected with the human immunodeficiency virus (HIV) can expect a healthy and long life. However, living with HIV does increase the risk of cancer. The reasons for this are multiple and include behavioural risk factors (smoking etc.) but many cancers can be attributed to the effects the virus has on the immune system, specifically its…
Breast cancer is rare for women under 40. So, a breast cancer diagnosis can be shocking news for a young woman to hear. “Breast cancer in young women can have its own risk factors and traits, and young women have their own considerations when deciding on a treatment,” says Nadine Tung, MD, head of breast medical oncology and cancer genetics at Beth Israel Deaconess Medical Center (BIDMC).…
Immunotherapy is a promising cancer treatment that uses genetically modified immune cells to fight cancer. It can be used as a primary treatment or in combination with other treatments such as radiation and chemotherapy to slow down or stop the growth of cancer cells and prevent them from spreading to other parts of the body. Chimeric Antigen Receptor (CAR)-T cell therapy, for instance, is a…
Cancer of unknown primary (CUP) can send radiologists on a frustrating scavenger hunt: metastases were detected but the primary cancer is nowhere to be seen. Professor Alwin Krämer, Head of the Clinical Cooperation Unit Molecular Haematology/Oncology at University Hospital Heidelberg and the German Cancer Research Center, explains strategies for dealing with CUP.
Two known gene mutations induce pathways that enhance pancreatic cancer’s ability to invade tissues and evade the immune system. Researchers report the molecular details of this process providing insights into druggable targets for immunotherapies. Mutations in the genes KRAS and TP53 are closely linked to pancreatic ductal adenocarcinoma, by far the most common type of pancreatic cancer.…
The World Health Organisation's (WHO) Essential Medicines List and List of Essential Diagnostics are core guidance documents that help countries prioritize critical health products that should be widely available and affordable throughout health systems. Now, updated versions of the two lists have been published, focusing on cancer and other global health challenges, with an emphasis on effective…
A strain of the common cold virus has been found to potentially target, infect and destroy cancer cells in patients with bladder cancer. No trace of the cancer was found in one patient following treatment with the virus. The researchers published their findings in the medical journal Clinical Cancer Research. Researchers from the University of Surrey and Royal Surrey County Hospital investigated…
Image analysis of prostate cancer is a challenging area for clinicians. The disease shows a low mutation burden compared to melanoma and stomach cancer, for example, making morpho-molecular correlation more difficult, and there is often very low inflammation. With the role of tumour infiltrating lymphocytes in prostate cancer currently unclear – and with the advent of new approaches to prostate…
Patients with biliary tract cancer have altered genetic architecture in some immune system receptor systems. This has been shown by researchers at Karolinska Institutet in Sweden in a new study published in the journal Gastroenterology. It is hoped that the discovery will lead to new effective immunotherapy for these difficult to treat tumour types. Biliary tract cancers, including…
Immuno-oncology is a therapy in which the body’s immune system treats a tumour. Dr Eric Borges, from the Research and Development Centre at Boehringer Ingelheim Pharma GmbH in Germany, explains why this is revolutionary. Unlike conventional cancer therapies, with immuno-oncology the tumour cell is not the direct target, it’s the patient’s immune system. The medication stimulates this to…
An anti-inflammatory drug called ketorolac, given before surgery, can promote long-term survival in animal models of cancer metastasis, a team of scientists has found. Furthermore, so-called "pro-resolution" therapies can also trigger the immune system to eliminate metastatic cells. The research also suggests that flanking chemotherapy with anti-inflammatory drugs can unleash anti-tumor…
Changes in certain sections of the genetic material of cancer cells, so-called microsatellites, can provide an important indication of whether immunotherapy may be successful in a patient with stomach or colorectal cancer. Scientists from Uniklinik RWTH Aachen, the German Cancer Research Center (DKFZ), the German Cancer Consortium (DKTK) and the National Center for Tumor Diseases Heidelberg (NCT)…
A new vaccination for malignant astrocytoma brings such patients hope. However, research is still in its infancy. We spoke with Professor Michael Platten, Medical Director of the Neurological Clinic at Medical University Mannheim, about the present state of research and the serious opportunities this presents. During the interview, he also revealed how cooperation with the pharmaceutical industry…
Advancing technology is allowing scientists increasingly to search for tiny signs of cancer and other health issues in samples of patients’ blood and urine. These “liquid biopsies” are less invasive than a traditional biopsy, and can provide information about what’s happening throughout the body instead of just at a single site. Now researchers at the University of Michigan Rogel Cancer…
Researchers at Mount Sinai have developed a novel approach to cancer immunotherapy, injecting immune stimulants directly into a tumor to teach the immune system to destroy it and other tumor cells throughout the body. The “in situ vaccination” worked so well in patients with advanced-stage lymphoma that it is also undergoing trials in breast and head and neck cancer patients, according to a…
Test more accurately identifies four mutations for which FDA-approved drugs exist and offers faster turn-around time between initial testing and commencement of therapy.
The first total-body positron emission tomography/computed tomography (PET/CT) that can acquire a 3D image of the human body in a single position received 510(k) clearance from the U.S. Food and Drug Administration (FDA) in January 2019. Its forthcoming commercial availability for clinical use in the United States later this year is the milestone achievement of a multi-institutional consortium…
Several research groups at Berlin Institute of Health (BIH) are working on digitally combating cancer. The main goal is to combine and jointly evaluate existing information. With 500,000 new cancer cases every year in Germany alone, it is worthwhile comparing experiences with different diagnostic and treatment methods, thus allowing more patients to benefit from the most promising approaches. In…
The first report from a phase II, multi-center clinical trial indicates that a newer, more aggressive form of radiation therapy — stereotactic radiation — can extend long-term survival for some patients with stage-IV cancers while maintaining their quality of life. The study is published in the January issue of International Journal of Radiation Oncology • Biology • Physics (Red Journal),…
Measuring tumour infiltrating lymphocytes (TILs) is gaining importance in immunotherapy, but other variables must also be considered to boost prognosis and prediction accuracy, a leading pathologist argued at EBCC 11 last March in Barcelona. When it comes to prognosis and prediction for immunotherapy, a potentially new variable is emerging – TILs – white blood cells that have left the blood…
The prospect of an actively personalized approach to the treatment of glioblastoma has moved a step closer with the recent publication in Nature of favorable data from the phase 1 study GAPVAC-101, testing a novel therapeutic concept tailored to specific characteristics of patients’ individual tumors and immune systems. For the first time, the feasibility of such a highly personalized form of…
Built as the first commercially available scanner to deliver truly digital PET, the Vereos PET/CT, from Philips, offers revolutionary Digital Photon Counting technology. The science behind this scanner evolution is ‘quite complicated’, agrees Piotr Maniawski, Director of Clinical Science Nuclear Medicine at Philips Healthcare, yet the improved performance is significant, particularly when…
Royal Philips has been leading two healthcare innovation projects that will receive government investment as part of major cross-sector collaborations with the NHS, academia and industry partners from the UK Government’s Industrial Strategy Challenge Fund, delivered through United Kingdom Research and Innovation (UKRI). A joint multi-million pound investment by government and industry partners,…
With new immunotherapy treatments for melanoma, recovery rates have risen dramatically – in some cases to around 50%. But they could be much higher. A new study led by researchers at the Weizmann Institute of Science showed, in lab dishes and animal studies, that a highly personalized approach could help the immune cells improve their ability to recognize the cancer and kill it.
Glioblastoma brain tumors can have an unusual effect on the body's immune system, often causing a dramatic drop in the number of circulating T-cells that help drive the body's defenses. Where the T-cells go has been unclear, even as immunotherapies are increasingly employed to stimulate the body's natural ability to fight invasive tumors. Now researchers have tracked the missing T-cells in…
An unexpected discovery that could bring new hope to cancer patients worldwide: Researchers from the University of California San Diego have identified a mechanism that could predict response to immunotherapy. The most effective weapon against the tumors may be handed to the scientists by the cancer cells themselves.
The exchange of a single amino acid building block in a metabolic enzyme can lead to cancer. In addition, it can impair the immune system. It thus blocks the body’s immune response in the battle against the mutant molecule and also impedes immunotherapy against brain cancer. This finding opens new insights into cancer development and progression and it also suggests that rethinking antitumor…
Two blood tests can predict which subset of men with advanced prostate cancer will likely not benefit from anti-androgen therapies, providing doctors and patient added clarity on treatment options, according to a study led by Duke Cancer Institute.
While treatments for HIV mean that the disease is no longer largely fatal, the world still lacks a true therapy that can eradicate the virus across a globally—and genetically different—population.
Babraham Institute researchers have shown that some tumours use not one but two levels of protection against the immune system. Knocking out one level boosted the protective effects of the second and vice versa. The research demonstrates that a two-pronged approach targeting both cell types simultaneously may offer a promising route for the development of new cancer immunotherapies.
An international Phase 3 study has found that a personalized glioblastoma vaccine may increase long-term survival in some patients.
T cells fight pathogens and tumors: Researchers from the Universities of Tübingen and Lübeck present a simple and fast method to rapidly assess their function. Due to its simplicity, reliability and versatility, it could be broadly implemented for basic research and in the clinical setting. Methods so far to test T-cell response were technically cumbersome and time-consuming and therefore only…
Taking a biopsy of a brain tumor is a complicated and invasive surgical process, but a team of researchers at Washington University in St. Louis is developing a way that allows them to detect tumor biomarkers through a simple blood test. Hong Chen, a biomedical engineer, and Eric C. Leuthardt, MD, a neurosurgeon, led a team of engineers, physicians and researchers who have developed a…
A vaccine may successfully turn off peanut allergy in mice, a new study shows. Just three monthly doses of a nasal vaccine protected the mice from allergic reactions upon exposure to peanut, according to research from the Mary H. Weiser Food Allergy Center at the University of Michigan. The study, funded by grants from Food Allergy Research and Education (FARE) and the Department of Defense, was…
Immunotherapy is taking center stage in imaging, but patient follow-up with CT is no cookie and may fall short in the peripheral limbs, brain and bone marrow. MRI offers specific benefits in these situations, and, combined with PET, it may bring even more results. Research must be carried out on quantitative techniques and tracers developed to fully exploit that potential, Prof. Dow-Mu Koh…
With immunotherapy, bigger lesions may be spotted on CT, but it doesn’t necessarily mean that the disease is progressing. As treatment works, it can cause what has become known as pseudo disease progression; and this is just one of the many revolutions immunotherapy is triggering in oncology imaging, Professor Clarisse Dromain (Lausanne/CH) explained as she opened the session dedicated to this…
Conventional chemotherapy in oncology is increasingly yielding to new procedures such as targeted therapy and immunotherapy. This results in changes for radiologists because new procedures require familiarisation with certain imaging to ensure that the treatment process is interpreted correctly.
The development of new procedures to monitor cancer treatments is gathering momentum. One such innovation is liquid biopsy. This new lab technique allows non-invasive identification, characterisation and monitoring of circulating tumour DNA. Thus, liquid biopsy can potentially revolutionise oncological diagnostics – and put a spoke in the wheel of radiology. High time to act, says Professor Dr…
The mass pursuit of a conspicuous suspect in Alzheimer’s disease may have encumbered research success for decades. Now, a new data analysis that has untangled evidence amassed in years of Alzheimer’s studies encourages researchers to refocus their investigations. Heaps of plaque formed from amyloid-beta that accumulate in afflicted brains are what stick out under the microscope in tissue…
A new genetic study by UK-based scientists suggests that immunotherapy drugs could prove to be an effective treatment for some breast cancer patients. Scientists from the Wellcome Trust Sanger Institute, near Cambridge – one of the world’s leading genome centres – and their collaborators, have identified particular genetic changes in a DNA repair mechanism in breast cancer. Led by Dr Serena…
T cells play a key role in the body’s immune response against pathogens. As a new class of therapeutic approaches, T cells are being harnessed to fight cancer, promising more precise, longer-lasting mitigation than traditional, chemical-based approaches. These “living drugs” are poised to transform medicine, with a growing number of cellular therapies receiving FDA-approval. A current…
Researchers in the Perelman School of Medicine at the University of Pennsylvania have identified a new therapeutic target for the treatment of melanoma. For decades, research has associated female sex and a history of previous pregnancy with better outcomes after a melanoma diagnosis. Now, a research team from Perelman School of Medicine at the University of Pennsylvania says it may have…
A team of scientists at the Keck School of Medicine of USC is looking to some deep sea dwellers to create a better way to develop cancer-fighting therapies. Harnessing the power of the enzymes that give these marine animals the ability to glow, the team created a test that makes it easy for researchers to see whether a therapy is having its intended effect — killing cancer cells. The results of…
Through gene therapy, researchers engineered blood-forming stem cells (hematopoietic stem/progenitor cells, or HSPCs) to carry chimeric antigen receptor (CAR) genes to make cells that can detect and destroy HIV-infected cells. These engineered cells not only destroyed the infected cells, they persisted for more than two years, suggesting the potential to create long-term immunity from the virus…
Using light-emitting nanoparticles, Rutgers University-New Brunswick scientists have invented a highly effective method to detect tiny tumors and track their spread, potentially leading to earlier cancer detection and more precise treatment. The technology could improve patient cure rates and survival times. “We’ve always had this dream that we can track the progression of cancer in real…
When immune cells invade the tumor, this is usually considered a good sign because the body's own immune system appears to be responding to the cancer. In the case of certain types of breast cancer immune cells, namely so-called tumor-infiltrating lymphocytes (TILs), these can determine survival rates and predict the usefulness of chemotherapy. This was shown by the largest meta study on TIL…
Genentech researchers have identified an enzyme that shifts pancreatic cancer cells to a more aggressive, drug-resistant state by epigenetically modifying the cells’ chromatin. The study, which will be published in the Journal of Cell Biology, suggests that targeting this enzyme could make pancreatic cancer cells more vulnerable to existing therapies that currently have only limited effect…
Loyola University Medical Center is the only Chicago center that participated in the pivotal clinical trial of a groundbreaking cancer treatment that genetically engineers a patient's immune system to attack cancer cells. Patrick Stiff, MD, director of Loyola's Cardinal Bernardin Cancer Center, is a co-author of the study, published in the New England Journal of Medicine. The treatment used in…
Johns Hopkins Kimmel Cancer Center researchers demonstrated that mice with ovarian cancer that received drugs to reactivate dormant genes along with other drugs that activate the immune system had a greater reduction of tumor burden and significantly longer survival than those that received any of the drugs alone. The study already spurred a clinical trial in ovarian cancer patients. The…
Scientists are using their increasing knowledge of the complex interaction between cancer and the immune system to engineer increasingly potent anti-cancer vaccines. Now researchers at the National Institute of Biomedical Imaging and Bioengineering (NIBIB) have developed a synergistic nanovaccine packing DNA and RNA sequences that modulate the immune response, along with anti-tumor antigens, into…
Combining molecular information and high contrast resolution may well improve current performance in colorectal cancer (CRC) cases, according to Vicky Goh, who presented the latest results on PET/MRI during the last European Society of Medical Oncology (ESMO) meeting in Madrid PET/MRI brings the best of both modalities together: high contrast to noise and high spatial resolution combined with…
Primary liver cancer is now the second leading cause of cancer-related death worldwide, and its incidences and mortality are increasing rapidly in the United Stated. In late stages of the malignancy, there are no effective treatments or drugs. However, an unexpected finding made by a team of University of California San Diego School of Medicine researchers sheds light on the development of a new…
Many tumors possess mechanisms to avoid destruction by the immune system. For instance, they misuse the natural “brakes” in the immune defense mechanism, which normally prevent an excessive immune response. Researchers at the University of Bonn have now been able to take off one of these brakes. The study, which involved colleagues from Hamburg and Würzburg, could pave the way for more…
Every cancer is different and every patient is different. This insight gained in personalised medicine prompted oncology researchers to focus more on the individual patient’s immune system. It is particularly the immune system’s ability to destroy cancer cells that raised hope.
Headlines, of late, have touted the successes of targeted gene-based cancer therapies, such as immunotherapies, but, unfortunately, also their failures.
Scientists from St. Jude Children’s Research Hospital and Fred Hutchinson Cancer Research Center have developed an algorithm that functions like a Rosetta Stone to help decipher how the immune system recognizes and binds antigens. The research should aid development of more personalized cancer immunotherapy and advance diagnosis and treatment of infectious diseases.
Scientists at a UK university are using the power of mass spectrometry to research critical processes in human prostate cancer.
Up to ten years ago only a handful of antibodies that could be detected in the blood were known to neurology.
At the MEDICA 2016 IMMS is presenting its first approaches for the personalized diagnostics of cancer using a prototype device. It was developed in the three-year research project INSPECT which started in June 2016.
‘Today Vienna is one of the top addresses with regard to breast cancer research,’ Professor Michael Gnant proudly reports – and he certainly knows what he is talking about.
Melanomas account among the eight most frequent deadly cancers in Europe and Northern America. Two major clinical criteria separate melanomas from most other cancers: the risk to die from a melanoma is a question of being less or more than 1 mm – and not a question of cm. About 95% of patients with melanomas ≤0.5 mm in thickness are clinically cured by early detection and appropriate melanoma…
NIBIB researchers have created a nanovaccine that could make a current approach to cancer immunotherapy more effective while also reducing side effects. The nanovaccine helps to efficiently deliver a unique DNA sequence to immune cells – a sequence derived from bacterial DNA and used to trigger an immune reaction. The nanovaccine also protects the DNA from being destroyed inside the body, where…
When two Spanish oncologists launched the first independent Spanish oncology forum this May in Madrid, European Hospital’s correspondent spoke with Dr Javier Cortés, co-organiser of the event, to find out more about its expected impact in their field.
The Ligand PD-L1 is one of the most important targets for cancer immunotherapy with checkpoint inhibitors. But not all tumors have sufficient quantities of PD-L1 ligands on their surface. Scientists from the German Cancer Consortium (DKTK) have now shown that different types of cancer possess different quantities of PD-L1-Gen copies. Genetic analysis of the PD-L1 gene may in the future help to…
When an immune T cell divides into two daughter cells, the activity of an enzyme called mTORC1, which controls protein production, splits unevenly between the progeny, producing two cells with different properties. Such "asymmetric division," uncovered by Johns Hopkins Kimmel Cancer Center researchers using lab-grown cells and specially bred mice, could offer new ways to enhance cancer…
Last year, scientists at the University of California San Francisco (UCSF) revealed that by measuring the proportion of both immune and cancerous cells in tumours, or ‘tumour purity,’ clinicians could more precisely predict the success of certain precision therapies. A key aspect of the discovery was access to over 10,000 samples constituting 21 different cancers.
The fates of immune cells can be decided at the initial division of a cell. Researchers at St. Jude Children’s Research Hospital have discovered that the production of daughter cells with different roles in the immune system is driven by the lopsided distribution of the signaling protein c-Myc. Nudging c-Myc in one direction or the other could make vaccines more effective or advance…
Small cell lung cancer is not usually detected until it is at an advanced stage, when metastases have already formed. Chemotherapy is very effective initially but, within a year, cancer recurs and this time does not respond to a course of chemotherapy. The research group headed by Gerhard Hamilton, University Department of Surgery at MedUni Vienna, has now managed to identify the reason for this…
Using a laser probe, neurosurgeons at Washington University School of Medicine in St. Louis have opened the brain’s protective cover, enabling them to deliver chemotherapy drugs to patients with a form of deadly brain cancer.
Checkpoint inhibitors can achieve a lasting treatment response in around 20% of some kinds of advanced cancer cases. ‘Immunotherapies are given the highest possible rating on the Magnitude of Clinical Benefit Scale of the European Society for Medical Oncology (ESMO), which assesses the actual clinical benefit of tumour treatments,’ emphasises Professor Christoph Zielinski MD, Head of the…
Healthcare, the world’s largest industry, is more than three times the size and value of the financial services sector, and is transforming faster than ever before, driving humanity to rethink the way we approach our health.
Bladder cancer is associated with high recurrence rates, necessitating prolonged surveillance and repeated treatments. As a result, it is one of the most challenging and costly of all solid tumours to manage. Although most patients present at an early stage with non-muscle-invasive bladder cancer (NMIBC), between 13% and 61% will experience recurrence within 1 year of initial transurethral…
A new injectable “biogel” is effective in delivering anti-cancer agents directly into cancerous tumours and killing them. This technology, developed by researchers at the University of Montreal Hospital Research Centre (CRCHUM), has already been successfully tested in the laboratory. If it works in patients, the therapy could one day revolutionize treatment for many forms of cancer.
Researchers from Medicine, Chemistry and Biological Sciences in the University’s Institute for Life Science (IfLS) have been collaborating with Microsoft Research UK to investigate the function of the antigen-presenting protein MHC1. Their research, which started more than a decade ago and has been part-funded by Cancer Research UK, has explored the pliability of the protein and how its ability…
One goal of immunotherapy is to rally a patient’s often over-burdened immune cells to effectively attack a tumor. Among foot soldiers on the immune front line is a subpopulation of white blood cells called “patrolling monocytes,” whose job is to cruise the bloodstream, cart off cellular debris, and block invasion of a less benign population of inflammatory cells.
When it comes to fending off disease and helping prevent people from falling ill, the body’s immune system – armed with T-cells that help eliminate cancer cells, virus-infected cells and more – is second to none. But exactly how the immune system works remains, in many ways, a mystery, as there are numerous cell types whose functions and interactions with our immune systems have not been…
Researchers compared an immunotherapy and a chemotherapy drug in patients with non-squamous non-small cell lung cancer (NSCLC) whose disease continued to progress after first-line chemotherapy. They found that nivolumab improved overall survival and was generally well tolerated. The results are significant because options for patients whose lung cancer progresses after initial treatment are…
A number of innovative research results were presented at the 24th Congress of the European Academy of Dermatology and Venereology that took place in Copenhagen from 7 to 11 October 2015. Some of these results are expected to impact medicine far beyond dermatology, demonstrating the innovative character of the specialty.
apceth announced a broad partnership with the Center for Molecular Medicine Cologne (CMMC), University of Cologne, to combine technologies and expertise, on the development of immunotherapies for solid tumors and haematological malignancies. The collaboration will start immediately and is based on combinations of Chimeric Antigen Receptor (CAR) T cells, developed at the laboratory of Prof Hinrich…
Many therapeutic cancer vaccines that are currently being developed are designed to direct the immune system against altered cancer-cell proteins.
The human immune system is usually very efficient in protecting the body against diseases by eliminating pathogens as well as infected, damaged or otherwise suspicious cells. However, it often fails because tumours have developed efficient strategies that hamper the system’s ability to detect and destroy the cancer cells. Report. Ludger Weß
The German Cancer Research Center (DKFZ) and Bayer HealthCare (Bayer) will extend their successful strategic research alliance in search of novel cancer therapeutics by focusing their activities also on the field of immunotherapy.
‘We aim to develop an understanding of which novel research activities could bring benefits for patients,’ explained Professor Christof von Kalle, Director of the Department of Translational Oncology, NCT (German National Centre for Tumour Diseases) and the German Cancer Research Centre (DKFZ), speaking on translational activities during the New Cancer Targets gathering in Heidelberg this…
Personalised cancer medicine is much discussed, with high expectations for biomolecular decoding of various tumours and the global pharma industry developing targeted drugs to attack tumours at a biomolecular level.
Across Europe an estimated 3.2 million new cases and 1.7 million deaths occur annually. By intensified cooperation in research, diagnosis and treatment, enormous advantages can be achieved. To progress the integration of knowledge and skills in this field, the first European Forum on Oncology was held this October in Berlin.
Trials for a new type of treatment for stroke that could help millions of people at risk of death or disability should commence in 2011. A research team in France has successfully completed laboratory tests of antibodies that protect the brain and reduce the side-effects of current therapy.
The so-called lymphoma, which are cancers of the immune system, originate in white blood cells. Pathological B cells, for instance, are responsible for the "diffuse large B cell lymphoma", which progress very aggressively if left untreated. Now a new approach for future therapy of this cancer has been found by an international research consortium. They present their research in the scientific…
Belgium and United Kingdom - Two researchers, Dr Charles Pilette, currently at the Pneumology Department, University Hospital of Louvain, St-Luc, Belgium, and Dr William Man, who is completing specialist clinical training in Respiratory Medicine and General Internal Medicine, in London, have received this year's awards for research into Chronic Obstructive Pulmonary Disease (COPD), granted by…
Prostate cancer, the most common neoplasm in men, often progresses from an androgen-dependant state (and is commonly treated by androgen ablation therapies) to a hormone-refractory stage, therefore making hormone therapy ineffective. The response duration to androgen ablation therapy is finite and ultimately most prostate cancer will become hormone-insensitive.
